Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer.

NEJM evidence·2026
Same author

A Randomized Trial Evaluating Personalized Versus Guideline-Based Well Follow-Up Strategies for Patients with Early Breast Cancer: Feasibility Outcomes.

Current oncology (Toronto, Ont.)·2026
Same author

Correction: Prospective study on <sup>18</sup>F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma.

British journal of cancer·2026
Same author

Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation Study.

Journal of medical Internet research·2026
Same author

Oncoplastic Surgery Versus Lumpectomy: Analysis of Oncological Outcomes and Surgical Complications in 1290 Breast Cancer Patients.

Current oncology (Toronto, Ont.)·2026
Same author

Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.

Breast cancer research and treatment·2026

Related Experiment Video

Updated: Jan 19, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K

Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information.

Susan J Robertson1, Greg R Pond2, John Hilton3

  • 1Eastern Ontario Regional Laboratory, Department of Pathology and Laboratory Medicine, The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada.

Clinical Breast Cancer
|September 26, 2019
PubMed
Summary

Predictive algorithms can identify patients unlikely to benefit from Oncotype DX (ODX) testing, potentially reducing costs. The Magee 3 equation showed high accuracy in predicting ODX scores, suggesting its use as a screening tool.

Keywords:
AdjuvantAlgorithmsBreast cancerPathologyRecurrence score

More Related Videos

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

495
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

1.2K

Related Experiment Videos

Last Updated: Jan 19, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

495
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

1.2K

Area of Science:

  • Oncology
  • Genomics
  • Biostatistics

Background:

  • Oncotype DX (ODX) testing is costly and its indiscriminate use offers limited value.
  • Predictive algorithms using standard clinicopathologic data can provide surrogate ODX scores.
  • Identifying patients who will not benefit from ODX testing can optimize resource allocation.

Purpose of the Study:

  • To evaluate if existing prognostic scores can identify patients unlikely to benefit from ODX testing.
  • To assess the utility of Magee equations, Gage Algorithm, and University of Tennessee predictive algorithm as ODX screening tools.

Main Methods:

  • Retrospective analysis of 302 invasive ductal breast cancer patients with available ODX scores.
  • Comparison of ODX scores with scores generated by Magee equations (1, 2, 3), Gage Algorithm, and University of Tennessee predictive algorithm.
  • Banding of ODX scores according to TAILORx results to validate predictive models.

Main Results:

  • High correlations were observed between predictive algorithms and ODX scores (0.7–0.9+).
  • Magee 3 equation demonstrated the highest robustness (>0.9 correlation).
  • Proposed cut-offs for Magee 3 scores could identify 51.9% of patients not requiring ODX testing, with 99.1% managed appropriately.

Conclusions:

  • The Magee 3 equation and other predictive algorithms show promise as screening tools for ODX testing.
  • Implementing these tools could significantly reduce the frequency of ODX testing.
  • Further validation in diverse patient populations is necessary.